Ovarian Cancer

Latest News

Botensilimab Plus Balstilimab Yields Enduring Responses in R/R Ovarian Cancer  | Image Credit: © Lars Neumann - stock.adobe.com.
Botensilimab Plus Balstilimab Yields Enduring Responses in R/R Ovarian Cancer

March 28th 2023

Patients with resistant or refractory ovarian cancer experience clinical benefits after receiving botensilimab plus balstilimab in the phase 1 C-800 study.

Niraparib maintenance therapy for recurrent ovarian cancer does not yield a significant overall survival benefit in an updated analysis of the phase 3 ENGOT-OV16/NOVA study.
Niraparib Yields Limited OS in Final Analysis for Ovarian Cancer

March 27th 2023

The Carolina Frailty Index Score indicates that patients with ovarian cancer classified as frail are highly more likely to die than patients classified as robust.
Index Score Informs Frailty Assessments in Ovarian Cancer

March 27th 2023

In the SOLAR phase 1b trial, a clinical benefit was observed when patients with RAS-mutated ovarian or endometrial cancer were given olaparib plus selumetinib.
Olaparib Plus Selumetinib Show Benefit in RAS-Mutated Ovarian and Endometrial Cancers

March 27th 2023

Dose Modification of Maintenance Niraparib May Not Impact PFS in Ovarian Cancer | Image Credit: © magicmine - stock.adobe.com.
Dose Modification of Maintenance Niraparib May Not Impact PFS in Ovarian Cancer

March 27th 2023

More News